The role of antibodies against hsp90 in the treatment of fungal infections

Publisher Website
Google Scholar
Abstract
Advances in antibody engineering have solved many of the problems inherent in traditional sources of antibodies, and about a quarter of all biotechnology-based drugs now in development are antibodies. This has come at a time when it is apparent that reliance on antibiotics alone is beginning to select out resistant pathogens, fungi being a prime example. The development of antibody-based therapeutics, such as Mycograb, against novel fungal targets offers a new approach to combating the spread of resistance and reducing mortality.

This publication has 0 references indexed in Scilit: